Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies

Cell Research

Volumn 22, Issue 8, 2012, Pages 1227-1245

  Steckel, Michael ^a   Molina Arcas, Miriam ^a   Weigelt, Britta ^a   Marani, Michaela ^a   Warne, Patricia H ^a   Kuznetsov, Hanna ^a   Kelly, Gavin ^a   Saunders, Becky ^a   Howell, Michael ^a   Downward, Julian ^a   Hancock, David C ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

KRAS; oncogene addiction; proteasome; synthetic lethal; topoisomerase

Indexed keywords

ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; BORTEZOMIB; CDC6 PROTEIN, HUMAN; CELL CYCLE PROTEIN; DEOXYCYTIDINE; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; DRUG DERIVATIVE; GATA2 PROTEIN, HUMAN; GEMCITABINE; KRAS PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEASOME; PROTEASOME INHIBITOR; PYRAZINE DERIVATIVE; RAS PROTEIN; SMALL INTERFERING RNA; TOPOTECAN; TRANSCRIPTION FACTOR GATA 2;

ALLELE; APOPTOSIS; ARTICLE; CELL SURVIVAL; CELL TRANSFORMATION; COLON TUMOR; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HUMAN; METABOLISM; MUTATION; PATHOLOGY; RNA INTERFERENCE; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

ALLELES; ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; COLONIC NEOPLASMS; DEOXYCYTIDINE; DNA TOPOISOMERASES, TYPE I; GATA2 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MUTATION; NUCLEAR PROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PROTO-ONCOGENE PROTEINS; PYRAZINES; RAS PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TOPOISOMERASE I INHIBITORS; TOPOTECAN; TRANSCRIPTIONAL ACTIVATION;

EID: 84865015653     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2012.82     Document Type: Article

References (35)

1. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003; 3:11-22. (Pubitemid 37328883)
2. Shirasawa S, Furuse M, Yokoyama N, Sasazuki T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 1993; 260:85-88. (Pubitemid 23122749)
3. Chin L, Tam A, Pomerantz J, et al. Essential role for onco-genic Ras in tumour maintenance. Nature 1999; 400:468-472. (Pubitemid 29361802)
4. Sharma SV, Gajowniczek P, Way IP, et al. A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 2006; 10:425-435. (Pubitemid 44693471)
5. Weir B, Zhao X, Meyerson M. Somatic alterations in the hu-man cancer genome. Cancer Cell 2004; 6:433-438. (Pubitemid 39469978)
6. Cully M, You H, Levine AJ, Mak TW. Beyond PTEN muta-tions: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 2006; 6:184-192. (Pubitemid 43292562)
7. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009; 136:823-837.
8. Hartwell LH, Szankasi P, Roberts CJ, Murray AW, Friend SH. Integrating genetic approaches into the discovery of anticancer drugs. Science 1997; 278:1064-1068. (Pubitemid 27517876)
9. Niles A. Apo-ONE™ homogeneous caspase-3/7 assay: robust, high-throughput apoptosis detection. Promega Notes 2002; 81:6-8.
10. Echeverri CJ, Beachy PA, Baum B, et al. Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods 2006; 3:777-779. (Pubitemid 44445821)
11. von Mering C, Jensen LJ, Snel B, et al. STRING: known and predicted protein-protein associations, integrated and trans-ferred across organisms. Nucleic Acids Res 2005; 33:D433-D437. (Pubitemid 40207910)
12. Kumar MS, Hancock DC, Molina-Arcas M, et al. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell 2012; 149:642-655.
13. Dajee M, Tarutani M, Deng H, Cai T, Khavari PA. Epidermal Ras blockade demonstrates spatially localized Ras promotion of proliferation and inhibition of differentiation. Oncogene 2002; 21:1527-1538. (Pubitemid 34226140)
14. Wang Y, Ngo VN, Marani M, et al. Critical role for transcrip-tional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells. Oncogene 2010; 29:4658-4670.
15. Scholl C, Frohling S, Dunn IF, et al. Synthetic lethal interac-tion between oncogenic KRAS dependency and STK33 sup-pression in human cancer cells. Cell 2009; 137:821-834.
16. Babij C, Zhang Y Kurzeja RJ, et al. STK33 kinase activity is nonessential in KRAS-dependent cancer cells. Cancer Res 2011; 71:5818-5826.
17. Luo J, Emanuele MJ, Li D, et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009; 137:835-848.
18. Sharma SV, Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev 2007; 21:3214-3231. (Pubitemid 350277749)
19. Sarthy AV, Morgan-Lappe SE, Zakula D, et al. Survivin deple-tion preferentially reduces the survival of activated K-Ras-transformed cells. Mol Cancer Ther 2007; 6:269-276. (Pubitemid 46206691)
20. Barbie DA, Tamayo P, Boehm JS, et al. Systematic RNA inter-ference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009; 462:108-112.
21. Chien Y Kim S, Bumeister R, et al. RalB GTPase-mediated activation of the IkappaB family kinase TBK1 couples innate immune signaling to tumor cell survival. Cell 2006; 127:157-170. (Pubitemid 44472624)
22. Meylan E, Dooley AL, Feldser DM, et al. Requirement for NF-kappaB signalling in a mouse model of lung adenocarci-noma. Nature 2009; 462:104-107.
23. Xue W, Meylan E, Oliver TG, et al. Response and resistance to NF-kappaB inhibitors in mouse models of lung adenocarci-noma. Cancer Discov 2011; 1:236-247.
24. Tong Q, Dalgin G, Xu H, Ting CN, Leiden JM, Hotamisligil GS. Function of GATA transcription factors in preadipocyte-adipocyte transition. Science 2000; 290:134-138.
25. Tsai FY, Keller G, Kuo FC, et al. An early haematopoietic de-fect in mice lacking the transcription factor GATA-2. Nature 1994; 371:221-226. (Pubitemid 24293019)
26. Cocker JH, Piatti S, Santocanale C, Nasmyth K, Diffey JF. An essential role for the Cdc6 protein in forming the pre-replica-tive complexes of budding yeast. Nature 1996; 379:180-182. (Pubitemid 26020203)
27. Boronat S, Campbell JL. Linking mitosis with S-phase: Cdc6 at play. Cell Cycle 2008; 7:597-601. (Pubitemid 351498997)
28. Yoshida K, Sugimoto N, Iwahori S, et al. CDC6 interaction with ATR regulates activation of a replication checkpoint in higher eukaryotic cells. J Cell Sci 2010; 123:225-235.
29. Gilad O, Nabet BY, Ragland RL, et al. Combining ATR sup-pression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner. Cancer Res 2010; 70:9693-9702.
30. Liu P, Leong T Quam L, et al. Activating mutations of N- and K-ras in multiple myeloma show different clinical associa-tions: analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood 1996; 88:2699-2706. (Pubitemid 26327523)
31. Dolma S, Lessnick SL, Hahn WC, Stockwell BR. Identifca-tion of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell 2003; 3:285-296. (Pubitemid 37443883)
32. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defned genetic elements. Nature 1999; 400:464-468. (Pubitemid 29361801)
33. Davies AM, Chansky K, Lara PN Jr., et al. Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339). J Thorac Oncol 2009; 4:87-92.
34. Boutros M, Bras LP, Huber W. Analysis of cell-based RNAi screens. Genome Biol 2006; 7:R66.
35. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998; 95:14863-14868. (Pubitemid 29003722)